



## Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : L74999TG2016PLC109280

May 22, 2020  
Secunderabad

To  
The Listing Department  
BSE Limited

Dear Sir,

**Sub.: Impact of Covid -19 on Vanta Bioscience Limited**  
**Ref: Disclosure under Reg 30 of SEBI (LODR) Regulations**

Dear Sir / Madam,

This is to inform that in view of the outbreak of Corona Pandemic in India and in view of the lockdown announced by the Central Government, Telangana and Tamil Nadu State Government, the company has taken all necessary precautions to ensure safety and wellbeing of all the employees and other stakeholders across all its offices

We wish to inform you that the company has now obtained the permission to work and accordingly, normal operations are being resumed at the Company's CRO facility at Gummidipudi, Tamilnadu, as per the SOP mandated by the Central and State authorities in this regard.

It is envisaged that impact of the COVID-19 pandemic, including that on financial condition and results of operations, future operations, capital and financial resources, liquidity, assets, internal financial control over financial reporting and disclosure controls and procedures, demand for products/services etc. would **not be too significant** in case of our company.

Though, there has been a lag in receivables from clients and also in availability of raw material for conducting some specific studies due to restriction placed on movement and transportation. However, **there is no long term major impact as such on the overall set up and functioning of the Company as on date.**

Further, it is anticipated that with work and transportation related relaxations being notified for various parts of the country and gradual start of economic activities would eventually result in cash flows and availability of raw materials as and when required for continuation of our studies.

The Company shall further provide regular updates as and when there are any material developments in this regard. Further, impact on the financial statements, if any due to the pandemic shall also be included in the financial statements submitted under Regulation 33 of SEBI (LODR) Regulations

This is for your information and dissemination to public at large.

Thanking you.

**FOR VANTA BIOSCIENCE LIMITED**  
**Scrip Code: 540729/ Scrip ID: VANTABIO**

  
**ZOHEB SAYANI**  
**COMPANY SECRETARY**

